Mediwhale, an AI-powered health diagnostics company, has raised $12 million in Series A2 funding to strengthen its global leadership in cardiovascular and metabolic disease prevention.
- Funding Details: Mediwhale raised $12M in Series A2 funding, led by Korea Development Bank, alongside Woori Venture Partners and others.
- Innovative Diagnostics: Mediwhale’s Reti-CVD uses AI to predict cardiovascular risk through simple retina scans, offering a radiation-free alternative to cardiac CT scans.
- Previous Funding: The company raised $2M in Series Pre-A (2021) and $9M in Series A (2023), bringing total funding to $23M.
- Future Plans: Funds will be used to improve AI algorithms, secure FDA approval for Reti-CVD, and expand globally, including new products for predicting chronic kidney disease.
Mediwhale is positioned to drive innovation in early disease detection, expanding its global reach and pushing the boundaries of AI-powered healthcare diagnostics for cardiovascular and metabolic diseases.
